Pharming Group Notice of Q3 Results

Conference call dial-in informationThursday, October 27, 202213:30 CET/07:30 ET Conference call dial-in informationThursday, October 27, 2022 13:30 CET / 07:30 ET Please note, the Company will only take questions from dial-in attendees Dial-in details:Netherlands(Local)          +31 85 888 7233 United Kingdom                +44 800 640 6441United Kingdom(Local)   +44 20 3936 2999 United States                     +1 855 979 6654United States(Local)        +1...

Netherlands, 12/10/2022 (informazione.it - comunicati stampa - varie)

Netherlands (Local)          +31 85 888 7233
United Kingdom                +44 800 640 6441
United Kingdom (Local)   +44 20 3936 2999
United States                     +1 855 979 6654
United States (Local)        +1 646 664 1960
All other locations            +44 20 3936 2999
https://webcast.openbriefing.com/pharming-q32022/ 

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands , and has employees around the globe who serve patients in over 30 markets in North America , Europe , the Middle East , Africa , and Asia-Pacific .

For more information, visit www.pharming.com or find us on LinkedIn.

Heather Robertson, Investor Relations & Corporate Communications Manager:
T: +31 71 5247 400
E: investor@pharming.com 

Victoria Foster Mitchell / Alex Shaw
T: +44 203 727 1000

Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/pharming-group-notice-of-q3-results-301646259.html